PT  - JOURNAL ARTICLE
AU  - Melina Michelen
AU  - Louise Sigfrid
AU  - Christiana Kartsonaki
AU  - Ian Shemilt
AU  - Claire Hastie
AU  - Margaret E. O’Hara
AU  - Jake C. Suett
AU  - Elisabeth A. Stelson
AU  - Polina Bugaeva
AU  - Dania T. Dahmash
AU  - Ishmeala Rigby
AU  - Daniel Munblit
AU  - Eli Harriss
AU  - Amanda Burls
AU  - Vincent Cheng
AU  - Janet T. Scott
AU  - Gail Carson
AU  - Piero Olliaro
AU  - Charitini Stavropoulou
TI  - Characterising Long Covid: a living systematic review update with controlled studies
AID  - 10.1101/2022.08.29.22279338
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.29.22279338
4099  - http://medrxiv.org/content/early/2022/08/30/2022.08.29.22279338.short
4100  - http://medrxiv.org/content/early/2022/08/30/2022.08.29.22279338.full
AB  - Background The clinical sequelae (Long Covid) of acute Covid-19 are recognised globally, yet the risk of developing them is unknown.Methods A living systematic review (second version). Bibliographical records from the C19 Living Map Long Covid ‘segment’ (22nd February 2022), Medline, CINAHL, Global Health, WHO Covid-19 database, LitCOVID, and Google Scholar (18th November 2021). We included studies with at least 100 people at 12 weeks or more post-Covid-19 onset and with a control group without confirmed Covid-19. Risk of bias was assessed using the Newcastle-Ottawa scale. Symptoms are aligned with the Post Covid-19 Condition Core Outcome Set. We present descriptive statistics and use meta-analysis to estimate the relative risk of experiencing Long Covid.Results Twenty-eight studies were included: 20 cohort, five case-controls, three cross-sectional. Studies reported on 242,715 people with Covid-19 (55.6% female) and 276,317 controls (55.7% female) in 16 countries. Most were of moderate quality (71%). Only two were set in low-middle-income countries and few included children (18%). The longest mean follow-up time was 419.8 (standard deviation 49.4) days post-diagnosis. The relative risk (RR) of experiencing persistent or new symptoms in cases compared with controls was 1.53 (95% CI: 1.50 to 1.56). The core outcomes with the highest increased risk were cardiovascular (RR 2.53 95% CI: 2.16 to 2.96), cognitive (RR 1.99; 95% CI: 1.82 to 2.17), and physical functioning (RR 1.85; 95% CI: 1.75 to 1.96).Conclusion SARS-CoV-2 infection is associated with a higher risk of new or persistent symptoms when compared with controls that can last over a year following acute Covid-19. There is still a lack of robust studies set in lower resourced settings and current studies have high heterogeneity and potential misclassifications of cases and controls. Future research should explore the role of vaccination and different variants on the risk of developing Long Covid.Systematic review registration The protocol was prospectively registered on the PROSPERO database (CRD42020211131).Section 1: What is already known?What is already known?Published evidence indicates a high prevalence of people affected by post-acute SARS-CoV-2 sequelae often referred to as Long Covid; yet these estimates are impacted by heterogeneity in study design and a lack of controlled studies and core outcome sets.Our first version of this review, looking at studies till March 2021, identified a breadth of reported symptoms of Long Covid affecting both those who were hospitalised during the acute phase and those managed in the community. We also identified a lack of studies including children and set in low-middle income countries.The most commonly reported symptoms identified were weakness, general malaise, fatigue, concentration difficulties, and breathlessness, suggesting Long Covid is a complex, heterogeneous condition.Section 2: What are the new findings?What are the new findings?To address the limitations identified, this first update of our ‘living’ systematic review provides a comprehensive summary of peer-reviewed published studies with a control group (till 22nd February 2022) on the risk of experiencing Covid-19 sequelae.Despite study limitations identifying control groups, our findings suggest that people with a confirmed previous SARS-CoV-2 infection are 1.5 times more likely to experience new or persisting symptoms at 12 or more weeks post-onset when compared to a control group.Mapped to the new Core Outcome set for Post-Covid-19 Condition, a framework for standardised assessment, our review identifies cardiovascular functioning, cognitive functioning, and physical functioning as the outcomes with highest increased risk for people post-SARS-CoV-2 infection compared to controls.Section 3: What do the new findings imply?What do the new findings imply?Our findings point to a clear association between exposure to SARS-CoV-2 and the risk of developing new or persistent symptoms, for some lasting longer than 12 months after the initial infection.Controlled studies on Long Covid should focus on improving quality to enable multisite metaanalysis by using standardised research protocols and by evaluating participants with multiple standardised diagnostic tests at various time points to capture transitory and intermittent symptoms and complications.To help inform health system planning and rehabilitation to improve outcomes for those affected, Long Covid research should focus on estimating the burden of post-acute SARS-CoV-2 in lower resourced settings, investigating the impact of vaccination and variants on Long Covid, and investigating therapeutic strategies.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. JCS declares he is an individual living with long-term symptoms of probable Covid-19. All other authors declare no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135] and the EU FP7 project PREPARE (602525).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article and its supplementary files.CIConfidence intervalCOSCore outcome setCovid-19Coronavirus diseaseEHRElectronic health recordsIQRInterquartile rangeISARICInternational Severe Acute Respiratory and emerging Infection ConsortiumLMICLow-middle income countryLSRLiving systematic reviewNOSNewcastle-Ottawa ScaleRoBRisk of biasRRRisk ratioSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus-2SDStandard deviationSWARStudy within a reviewVASVisual analogue scaleWHOWorld Health Organization